Health Care/Hospital

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the...

2026-03-25 20:00 4353

Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs

The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world today * The Launch of STELA: Bioptimus is establishing the largest clinically linked multimodal ...

2026-03-25 19:00 4271

WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. Th...

2026-03-25 18:22 5765

HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering

Listing milestone positions HanchorBio to strengthen institutional visibility, advance itsFBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases TAIPEI, SHANGHAI and SAN FRANCISCO, March 25, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a globa...

2026-03-25 18:00 4387

VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial

* Pivotal Phase II/III clinical trial underway, aiming for US and European market approval in 2028 * A 'truly transformative' regenerative medicine targeting a multi-million patient population with no existing curative treatment * Fully biological transplant eliminates need for immunosuppres...

2026-03-25 17:11 3717

Why Chronic Eczema Can Last for Decades, and What a Recent Case Is Revealing

Tangs Clinical TCM Highlights Why Chronic Eczema Can Persist for Decades SINGAPORE, March 25, 2026 /PRNewswire/ -- A recent patient case managed by Tangs Clinical TCM has shed light on why chronic eczema can last for years, and how long-term, structured management may influence symptom patterns o...

2026-03-25 15:40 2397

BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States

BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosing SUZHOU, China, March 25, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (SSE: 688166, "BrightGene" or "the Company") today announced positive topline results f...

2026-03-25 14:32 4155

Asia Pacific Consumers Lack Confidence to Achieve Economic Goals - Herbalife Survey

HONG KONG, March 25, 2026 /PRNewswire/ -- Herbalife, a premier health and wellness company and community and platform, released new findings from itsAsia Pacific (APAC) Health and Economic Empowerment Survey 2025, where only two in five (43%) consumers feel very empowered to improve their economi...

2026-03-25 11:00 12673

Open-Sourcing to Empower, AI to Lead Medicine: "SurgMotion", the Best-in-class Surgical Video Foundation Model, Officially Launched

HONG KONG, March 25, 2026 /PRNewswire/ -- On 24 March, the Centre for Artificial Intelligence and Robotics (CAIR), Hong Kong Institute of Science & Innovation (HKISI), and the Chinese Academy of Sciences unveiled "SurgMotion" — a surgical video foundation model — at the Hong Kong Science and Tech...

2026-03-25 11:00 6140

Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab

HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first...

2026-03-25 10:40 5483

From SCAN to SPARK: Galaxy Brain Scientific Enables a New Paradigm in Non-invasive, Personalized Precision Treatment for Parkinson's Disease

BEIJING, March 24, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study in Nature Neuroscience demonstrating that Deep Brain Stimulation (DBS) achieves therapeutic efficacy in Parkinson's disease...

2026-03-25 10:34 4103

Hope Medicine Announces First Patient Dosed in the Phase III Clinical Trial for Endometriosis

SHANGHAI, March 24, 2026 /PRNewswire/ -- Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III clinical trial of HMI-115, its first-in-class monoclonal antibody with global rights, for the treatm...

2026-03-25 08:08 5176

Fosun Pharma Announces 2025 Annual Results

Innovation and Globalization Propel Fosun Pharma's High-Quality Growth SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company", stock code: 600196.SH; 02196.HK), an innovation-driven global pharmaceutical and healthcare group, announced its 2025 annual operating r...

2026-03-24 22:47 4772

BIOTRONIK Leaps Forward with Next‑Generation Leadless Pacing

* International BIO-LivIQ Study Will Generate Evidence for Global LivIQ Leadless Pacemaker Approvals * Far-Field Sensing and AV-Synchronous Pacing Performance Will be Validated by Real World Clinical Data BERLIN, March 24, 2026 /PRNewswire/ -- BIOTRONIK today announced the initiation of its g...

2026-03-24 22:06 3015

Datasea (NASDAQ: DTSS) Announces Initial U.S. Commercial Rollout and Commercialization Pathway for Acoustic Technology-Enabled Wellness Care Robots

Early-stage deployments across multiple U.S. regions expected to support initial service revenue generation and scalable commercialization model BEIJING, March 24, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in acoustic high-te...

2026-03-24 21:30 5309

ZEISS expands ophthalmic workflow portfolio in Canada with enhanced diagnostic, visualization and therapeutic solutions for precision eye care

* Expanded treatment and visualization capabilities within posterior care workflows: ICGA for ZEISS CLARUS 700 offers FA + ICG simultaneous capture to help support clinical assessment and streamline the diagnostic process; ZEISS VISULAS green, now available with ZEISS SLT, offers dependable ret...

2026-03-24 21:00 3946

Zocdoc Launches The AI-Informed Patient Report, Revealing How Patient Use of AI Is Reshaping the Patient-Provider Relationship

New findings highlight rising—yet hidden—patient use of AI and surprisingly optimistic providers, pointing to an emerging "triangle of care" NEW YORK, March 24, 2026 /PRNewswire/ -- Zocdoc, the healthcare access infrastructure connecting patients to great care, today releasedThe AI-Informed Pati...

2026-03-24 21:00 2634

Ping An Good Doctor Reports 2025 Annual Results: Corporate Health Management Business Posts Strong Growth; AI Healthcare Deployment Accelerates

HONG KONG, March 24, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its annual results for the year ended December 31, 2025. In 2025, the Company recorded total revenue of RMB5.47 billion, up 13.7% yea...

2026-03-24 20:37 4422

HKeyBio Launches HKEY-NHP-onChip™ 1.1: World's First NHP In Vitro Model for Autoimmune and Allergic Diseases

The integrated organ-on-chip platform offers 10–100x cost efficiency and 80% reduction in animal use, bridging the gap between preclinical NHP research and human clinical success. SUZHOU, China, SAN FRANCISCO and BOSTON, March 24, 2026 /PRNewswire/ -- HKeyBio, a global leading CRO specializing in...

2026-03-24 20:30 3314

Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study

Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetes CARY, N.C. and NEW YORK, March 24, 2026 /PRNewswire/ -- Continuity Biosciences and Breakthrough T1D, the leading global type 1 diabetes (T1D) advocacy organization, today ann...

2026-03-24 20:00 2602
1 ... 29303132333435 ... 858